Ultomiris
Ultomiris
Ultomiris is a medication used for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody-positive as well as those with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
It is natural to think you are alone when you are diagnosed with PNH, because it is a rare disease. We are here to help you be successful.
Administration Information
Ultomiris is given as an IV infusion every 8 weeks after 2 initial doses.
Potential Side Effects
WARNING:
SERIOUS MENINGOCOCCAL INFECTIONS: Immunize patients with
meningococcal vaccines at least 2 weeks prior to administering the first dose
of Ultomiris.
Meningococcal vaccination (both conjugate and serogroup B) are required
prior to initiating Ultomiris infusions.
Helpful Resources
Patient Forms
Before you attend your first appointment at Omega Health, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices and Patient Rights and Responsibilities are for reference only. Please contact us if you have any questions!
Patient Consent Form
Print & Sign
HIPAA Privacy Authorization Form
Print & Sign
Notice of Privacy Practice
Read
Patient Rights and Responsibilities
Read
Appointment Lateness and Cancelation
Read
